HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma.

Abstract
Data regarding the efficacy and safety of methotrexate (MTX) in adults with localized scleroderma (LoS) is scarce. This study gathered data from a retrospective cohort of adult patients with LoS (n?=?107), treated with MTX (1993-2015). MTX drug survival and predictors thereof were analysed. After 1 and 2 years, 26% and 63% of patients stopped MTX due to disease remission, respectively. Patients with younger age at MTX initiation (hazard ratio (HR) 1.159 (95% confidence interval (CI) 1.052-1.277)) and those with no other autoimmune diseases (HR 3.268 (95% CI 1.334-8.009)) more often stopped MTX due to disease remission. In addition, 24% of patients stopped MTX due to treatment failure within one year. Patients with circumscribed superficial LoS (HR 0.221 (95% CI 0.081-0.601)) experienced treatment failure less often than those with other LoS subtypes. Finally, adding folic acid (HR 0.184 (95% CI 0.079-0.425)) and reducing treatment delay (HR 1.056 (95% CI 1.004-1.112)) could be the most important factors in minimizing MTX treatment failure in LoS in clinical practice.
AuthorsJorre S Mertens, Juul M van den Reek, Wietske Kievit, Peter C M van de Kerkhof, Rogier M Thurlings, Tim R D Radstake, Marieke M B Seyger, Elke M G J de Jong
JournalActa dermato-venereologica (Acta Derm Venereol) Vol. 96 Issue 7 Pg. 943-947 (Nov 02 2016) ISSN: 1651-2057 [Electronic] Sweden
PMID26983450 (Publication Type: Journal Article)
Chemical References
  • Antirheumatic Agents
  • Folic Acid
  • Methotrexate
Topics
  • Adolescent
  • Adult
  • Aged
  • Antirheumatic Agents (administration & dosage, adverse effects, therapeutic use)
  • Child
  • Child, Preschool
  • Female
  • Folic Acid (therapeutic use)
  • Humans
  • Infant
  • Male
  • Methotrexate (administration & dosage, adverse effects, therapeutic use)
  • Middle Aged
  • Remission Induction
  • Retrospective Studies
  • Scleroderma, Localized (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: